Changes in Hong Kong stocks | Tongyuankang Pharmaceutical-B (02410) opens nearly 15% innovative drug TY-9591 tablets approved for listing with conditions

The Zhitong Finance App learned that Tongyuankang Pharmaceutical-B (02410) was nearly 15% higher. As of press release, it had risen 14.99% to HK$7.825, with a turnover of HK$2,758,300.

According to the news, on the evening of August 27, Tongyuankang Pharmaceutical announced that the new-generation EGFR-TKI innovative drug deuterosenitinib mesylate tablets (TY-9591 tablets) independently developed by the company has obtained approval from the China National Drug Administration (NMPA) for marketing with conditions. The indications are having epidermal growth factor receptor (EGFR) exon 19 deficiency (19DEL) or exon 21 (L858R) replacement mutations accompanied by central nervous system (CNS) metastasis) First-line treatment for adult patients.

Aitinib mesylate tablets are a new generation of highly selective, irreversible oral EGFR-TKI independently developed by Tongyuankang Pharmaceutical. It is an innovative variant for differentiating deuterium generation of osidinib. Through unique structural optimization, the drug effectively reduces the production of toxic metabolites, has better pharmacokinetic characteristics, and shows outstanding clinical efficacy and safety advantages in people with lung cancer brain metastasis and EGFR L858R sensitive mutations. At present, the company has laid out a number of clinical studies of single drugs and combination drugs around this product, covering all types of segmented indications for advanced non-small cell lung cancer.